Nuvectis Pharma (NVCT) AI Stock Analysis

• Market Cap: $170.70M
• Dividend Yield: N/A
• Average Volume (3M): 149.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.66
• Revenue Growth: N/A
• EPS Growth: 22.99%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 20,893,507
• 10 Day Avg. Volume: 78,196
• 30 Day Avg. Volume: 149,563
• PEG Ratio: 4.60
• Price to Book (P/B): 7.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -14.38
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: -17.45
• Enterprise Value/Gross Profit: -15.90
• Enterprise Value/Ebitda: -1.72
• 1Y Price Target: $17.33
• Price Target Upside: 117.99% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 48 Neutral
• Price Target: ―

Nuvectis Pharma's stock score reflects the high-risk, high-reward nature of biotechnology investments. The company's financial performance is weak due to consistent losses and negative cash flow, which significantly impacts the score. However, strong technical indicators provide some optimism, though caution is advised due to overbought signals. The valuation is challenging due to a lack of earnings and dividends, underscoring the speculative nature of the stock.

Positive Factors

Drug Study Results

Positive results from Drug-Drug Interaction (DDI) study further supports use of NXP900 in combination therapies.

Financial Status

Nuvectis ended with $18.5M in cash and no debt, and closed an equity offering receiving net proceeds of $14.4M, providing sufficient capital to fund operations into 2027.

Safety Profile

No serious or severe adverse events were observed in the NXP900 study, indicating a favorable safety profile for potential combinations.

Negative Factors

Adverse Events

The interim data found that NXP900 was very well tolerated with the majority of the adverse events being gastrointestinal related and none requiring any therapeutic interventions.

Safety Concerns

Thrombocytopenia seen in Phase 1 raises safety concerns for NXP800, which is considered an asset upside and not included in the valuation.

Nuvectis Pharma Business Overview & Revenue Model

Company Description

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

How the Company Makes Money

Nuvectis Pharma makes money primarily through the development and commercialization of its proprietary cancer therapies. The company's revenue model includes licensing agreements, partnerships with other pharmaceutical companies, and potentially the sale of its products upon receiving regulatory approval. Nuvectis Pharma may also generate income through milestone payments and royalties from its collaborations and partnerships. The company's earnings are significantly influenced by its ability to successfully bring drug candidates to market, navigate complex regulatory environments, and establish strategic alliances with key stakeholders in the healthcare industry.

Nuvectis Pharma Financial Statement Overview

Summary

Nuvectis Pharma is in a typical biotechnology firm position, heavily involved in R&D with no revenue generation yet. While the company's lack of debt and ability to raise funds are positive, the consistent losses and negative cash flows present significant financial risks. Achieving commercialization and revenue growth is critical for future financial stability and success.

Income Statement

Nuvectis Pharma has consistently reported zero revenue over the past years, indicating a lack of commercialized products or services. The company is facing substantial net losses, with a net income of -$19 million in 2024. This lack of revenue and consistent losses reflect the high-risk nature of biotech firms in the R&D phase, struggling to achieve profitability.

Balance Sheet

The balance sheet reveals a precarious financial position, with a low debt-to-equity ratio due to no reported debt, which is a positive aspect. However, the company's equity has been eroding, and the equity ratio has been decreasing over the years. The company's ability to finance operations without significant debt is a strength, but the declining equity raises concerns about future financial stability.

Cash Flow

Cash flows highlight significant challenges with negative operating cash flow and free cash flow, though there is a positive trend in financing cash flows, suggesting reliance on external funding. The company's negative cash flow from operations and lack of free cash flow growth underscore the need for successful product development and commercialization to achieve sustainable cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	149.00K	0.00	0.00
Gross Profit	0.00	-22.90M	-19.09M	-12.89M	0.00
EBITDA	-19.00M	-22.90M	-19.23M	-12.89M	0.00
Net Income	-19.00M	-22.26M	-18.79M	-12.89M	-10.00K
Balance Sheet
Total Assets	18.61M	19.18M	20.41M	6.66M	0.00
Cash, Cash Equivalents and Short-Term Investments	18.53M	19.13M	19.99M	5.74M	0.00
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	8.89M	6.98M	6.19M	17.66M	10.00K
Stockholders Equity	9.71M	12.20M	14.22M	-11.01M	-10.00K
Cash Flow
Free Cash Flow	-12.25M	-15.95M	-13.56M	-9.50M	24.00K
Operating Cash Flow	-12.25M	-15.95M	-13.56M	-9.50M	24.00K
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	11.65M	15.09M	27.81M	15.25M	0.00

Nuvectis Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVCT, the sentiment is Negative. The current price of 7.95 is above the 20-day moving average (MA) of 7.86, below the 50-day MA of 8.66, and above the 200-day MA of 7.51, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 46.01 is Neutral, neither overbought nor oversold. The STOCH value of 61.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NVCT.

Nuvectis Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$432.82M	―	-41.31%	―	―	-7.93%
Sector *	52 Neutral	kr5.61B	11.26	-62.48%	1.93%	26.20%	22.87%
THRD	49 Neutral	$245.95M	―	-19.94%	―	―	-14.76%
NVCT	48 Neutral	$170.70M	―	-115.28%	―	―	22.99%
MNPR	48 Neutral	$251.15M	―	-54.27%	―	―	-35.23%
IMMP	47 Neutral	$227.73M	―	-31.16%	―	―	15.14%
HUMA	42 Neutral	$370.73M	―	-257.38%	―	―	-17.92%